Aethlon Medical (NASDAQ:AEMD) Shares Pass Below 200-Day Moving Average – Should You Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.40 and traded as low as $2.66. Aethlon Medical shares last traded at $2.66, with a volume of 46,450 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, October 8th. Wall Street Zen raised Aethlon Medical to a “sell” rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and an average target price of $560.00.

Aethlon Medical Price Performance

The firm has a market capitalization of $2.02 million, a price-to-earnings ratio of -0.12 and a beta of 1.64. The business’s 50 day moving average price is $4.30 and its 200-day moving average price is $9.40.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, November 12th. The medical equipment provider reported ($3.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04). As a group, analysts expect that Aethlon Medical, Inc. will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.